HealthQuill Johnson & Johnson
Johnson & Johnson’s combination therapy for treating a certain form of cancer without chemotherapy, has been shown to extend patients' lives by more than a year, according to a company statement.
Drugs Health Medical Pharma

J&J’s combination extends lives of cancer patients versus rival drug

Johnson & Johnson’s combination therapy for treating a certain form of cancer without chemotherapy, has been shown to extend patients' lives by more.

Read More
Johnson & Johnson has discontinued its mid-stage trial, evaluating an antiviral drug, mosnodenvir, for the prevention of dengue.
Drugs Health Pharma

Johnson & Johnson stops mid-stage trial of drug for dengue prevention

Johnson & Johnson has discontinued its mid-stage trial, evaluating an antiviral drug, mosnodenvir, for the prevention of dengue.

Read More
Johnson & Johnson will invest $2 billion to build a biologics manufacturing facility in Wilson, North Carolina, anticipating new products planned by the decade's end.
Drugs Health Pharma

J&J to build $2b facility in North Carolina to make future products

 HQ Team October 2, 2024: Johnson & Johnson will invest $2 billion to build a biologics manufacturing facility in Wilson, North Carolina, anticipating.

Read More
Johnson & Johnson plans to acquire Israel’s privately-held V-Wave Ltd., for an upfront payment of $600 million, according to a statement from the US-based company.
Drugs Health Pharma

J&J plans to acquire Israel’s V-Wave by paying $600 million upfront

Johnson & Johnson plans to acquire Israel’s privately-held V-Wave Ltd., for an upfront payment of $600 million, according to a statement from the.

Read More
Johnson & Johnson will acquire Proteologix, Inc., a privately-held biotechnology company, for $850 million in cash, according to a statement.
Drugs Health Pharma

Johnson & Johnson to buy Proteologix Inc., for $850 million in cash

HQ Team May 17, 2024: Johnson & Johnson will acquire Proteologix, Inc., a privately-held biotechnology company, for $850 million in cash, according to.

Read More
Johnson & Johnson announced that USFDA had approved a bi-weekly dose of its blood cancer therapy Tecvayli.
Drugs Health Pharma

Johnson & Johnson’s blood cancer medicine cleared for bi-weekly use

HQ Team February 21, 2024: Johnson & Johnson announced that USFDA had approved a bi-weekly dose of its blood cancer therapy Tecvayli. The regulatory.

Read More
The USFDA is probing cancer therapies of Gilead Sciences, Johnson & Johnson and Novartis following reports of malignancies in patients who received treatment.
Drugs Health Pharma

FDA probing T cell cancer therapies of Gilead Sciences, Novartis, J & J

HQ Team November 29, 2023: The USFDA is probing cancer therapies of Gilead Sciences, Johnson & Johnson and Novartis following reports of malignancies.

Read More
Johnson & Johnson will apply with the USFDA to start clinical trials in the second half of 2024 for its robotic surgical system.
Health Medical Pharma

J&J to file USFDA request to start trials for surgical robots

Johnson & Johnson will apply with the USFDA to start clinical trials in the second half of 2024 for its robotic surgical system.

Read More
GSK, a British pharmaceutical company, will pay $1 billion to Johnson & Johnson for transferring exclusive global rights to develop and commercialise the US company’s hepatitis B therapy.
Drugs Health Pharma

GSK to pay $1 billion to acquire exclusive rights for J&J hepatitis B therapy

 HQ Team November 1, 2023: GSK, a British pharmaceutical company, will pay $1 billion to Johnson & Johnson for transferring exclusive global rights.

Read More
Johnson & Johnson has decided to halt an experimental trial, in its final stages, on a drug to treat a form of hypertension, according to a company statement.
Drugs Health Pharma

J&J halts final phase of trials of a drug to treat hypertension, says “futile” 

HQ Team September 7, 2023: Johnson & Johnson has decided to halt an experimental trial, in its final stages, on a drug to.

Read More